中創新航(03931.HK)與印度車企Ashok Leyland就當地電池項目合作
印度車企Ashok Leyland披露,與中創新航(03931.HK)建立長期獨家合作關係。集團將在印度投資本地化電池項目,除滿足自身電動車品牌需求外,亦將供應汽車產業與儲能領域的非自用市場;有關項目預計未來7至10年投入超過500億盧比資金,摺合約44.36億港元。
Ashok Leyland行政總裁Shenu Agarwal指,新電池業務初期聚焦汽車領域,後續將擴展至儲能系統等非汽車應用。集團將設立國際研發中心,推動電池材料、回收技術、電池管理系統與先進製程等創新研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.